This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (10)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Women's Health, Other  • Alert me on articles by topic

The Estrogen Connection

Raymond N. DuBois, MD, PhD

JAMA. 2004;291:2488-2489.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of THE JOURNAL, Terry et al¹ report that aspirin use in women is associated with a significant reduction in the risk of breast cancer, especially for hormone receptor–positive tumors. Previous studies have examined the relationship between breast cancer risk and aspirin or other nonsteroidal anti-inflammatory drug (NSAID) use but have not delineated different subtypes of breast cancers to determine this kind of correlation. This report is the first to examine whether the protective effect of aspirin varies with estrogen receptor (ER) or progesterone receptor (PR) status. With the genomic and proteomic revolution well underway, it is becoming quite clear that there are distinct differences in molecular signatures between tumors derived from the same organ. It is well known that the hormonal responsiveness of breast cancers is important for determining the treatment regimen and can affect the clinical outcome. Thus, it is not . . . [Full Text of this Article]

Author Affiliations: Departments of Medicine, Cell-Developmental Biology and Cancer Biology, The Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tenn.

RELATED ARTICLE

Association of Frequency and Duration of Aspirin Use and Hormone Receptor Status With Breast Cancer Risk
Mary Beth Terry, Marilie D. Gammon, Fang Fang Zhang, Heba Tawfik, Susan L. Teitelbaum, Julie A. Britton, Kotha Subbaramaiah, Andrew J. Dannenberg, and Alfred I. Neugut
JAMA. 2004;291(20):2433-2440.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Modulation of Breast Cancer Risk by Nonsteroidal Anti-inflammatory Drugs
Howe and Lippman
JNCI J Natl Cancer Inst 2008;100:1420-1423.
FULL TEXT  

Nonsteroidal Anti-inflammatory Drug Use and Serum Total Estradiol in Postmenopausal Women
Hudson et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:680-687.
ABSTRACT | FULL TEXT  

EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells: EVIDENCE OF A BRCA1 AND p300 EXCHANGE
Subbaramaiah et al.
J. Biol. Chem. 2008;283:3433-3444.
ABSTRACT | FULL TEXT  

C-Reactive Protein and Risk of Breast Cancer
Zhang et al.
JNCI J Natl Cancer Inst 2007;99:890-894.
ABSTRACT | FULL TEXT  

IL6, Aspirin, Nonsteroidal Anti-inflammatory Drugs, and Breast Cancer Risk in Women Living in the Southwestern United States
Slattery et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:747-755.
ABSTRACT | FULL TEXT  

Daily aspirin reduces risk of breast cancer, study finds
Hopkins Tanne
BMJ 2004;328:1336.
FULL TEXT